ibrutinib-话题@MedSci

#ibrutinib#

19篇内容 | 1304人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2179694, encodeId=f39621e969468, content=<a href='/topic/show?id=674769813be' target=_blank style='color:#2F92EE;'>#甲氨蝶呤#</a> <a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a> <a href='/topic/show?id=3d5d22290a4' target=_blank style='color:#2F92EE;'>#中枢神经系统淋巴瘤#</a>, objectTitle=老年原发中枢神经系统淋巴瘤患者一线大剂量甲氨蝶呤化疗后Ibrutinib维持的2期研究, objectType=article, longId=807808, objectId=932480e80831, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=932480e80831, replyNumber=0, likeNumber=87, createdTime=2024-01-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=932480e80831, moduleTitle=老年原发中枢神经系统淋巴瘤患者一线大剂量甲氨蝶呤化疗后Ibrutinib维持的2期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=932480e80831)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1603222, encodeId=4bb616032225d, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=72, createdTime=2022-01-17, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603221, encodeId=4873160322119, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=0, createdTime=2021-10-07, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603220, encodeId=ce1716032207f, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=JACC：Ibrutinib药物会出现严重的心脏毒性反应, objectType=article, longId=180029, objectId=e66a1800297e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e66a1800297e, replyNumber=0, likeNumber=100, createdTime=2019-09-27, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e66a1800297e, moduleTitle=JACC：Ibrutinib药物会出现严重的心脏毒性反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e66a1800297e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603219, encodeId=9789160321925, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=NEJM：venetoclax联合ibrutinib一线治疗慢性淋巴细胞白血病, objectType=article, longId=167377, objectId=0a8416e377e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a8416e377e9, replyNumber=0, likeNumber=0, createdTime=2019-06-02, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a8416e377e9, moduleTitle=NEJM：venetoclax联合ibrutinib一线治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a8416e377e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603218, encodeId=d75b160321804, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, objectType=article, longId=140766, objectId=ed6f140e66a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed6f140e66a3, replyNumber=0, likeNumber=82, createdTime=2018-06-15, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed6f140e66a3, moduleTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed6f140e66a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603217, encodeId=9d91160321eb9, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Blood：Ibrutinib治疗慢性移植物抗宿主病的疗效。, objectType=article, longId=113369, objectId=5ed111336960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ed111336960, replyNumber=0, likeNumber=108, createdTime=2017-09-21, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ed111336960, moduleTitle=Blood：Ibrutinib治疗慢性移植物抗宿主病的疗效。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ed111336960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603216, encodeId=4f9a16032161f, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=JCO：Ibrutinib治疗慢性淋巴细胞白血病后失败怎么办？抗CD19抗体提供新思路, objectType=article, longId=106003, objectId=3d7610600326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7610600326, replyNumber=0, likeNumber=74, createdTime=2017-07-21, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7610600326, moduleTitle=JCO：Ibrutinib治疗慢性淋巴细胞白血病后失败怎么办？抗CD19抗体提供新思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7610600326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603215, encodeId=2bde1603215b4, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=JCI:通过Ibrutinib治疗可改善白血病患者的T细胞数量和功能, objectType=article, longId=105982, objectId=6ad6105982a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad6105982a9, replyNumber=0, likeNumber=96, createdTime=2017-07-21, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad6105982a9, moduleTitle=JCI:通过Ibrutinib治疗可改善白血病患者的T细胞数量和功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad6105982a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603214, encodeId=3293160321439, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？, objectType=article, longId=85769, objectId=337785e6950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=337785e6950, replyNumber=0, likeNumber=0, createdTime=2016-12-29, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=337785e6950, moduleTitle=Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=337785e6950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603213, encodeId=bb99160321382, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=ASH 2016：Ibrutinib治疗慢性CVHD，疗效如何？, objectType=article, longId=84924, objectId=d30484924e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d30484924e5, replyNumber=0, likeNumber=85, createdTime=2016-12-22, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d30484924e5, moduleTitle=ASH 2016：Ibrutinib治疗慢性CVHD，疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d30484924e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603212, encodeId=97101603212a4, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Lancet Oncol：Ibrutinib治疗超高危CLL，风险获益良好, objectType=article, longId=79395, objectId=3854e939580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3854e939580, replyNumber=0, likeNumber=83, createdTime=2016-10-08, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3854e939580, moduleTitle=Lancet Oncol：Ibrutinib治疗超高危CLL，风险获益良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3854e939580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603211, encodeId=4f0e1603211c4, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥, objectType=article, longId=60350, objectId=a90660350f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90660350f4, replyNumber=0, likeNumber=89, createdTime=2015-12-08, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90660350f4, moduleTitle=NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90660350f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603210, encodeId=1cba160321001, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病, objectType=article, longId=52412, objectId=edd55241231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd55241231, replyNumber=0, likeNumber=93, createdTime=2015-06-25, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd55241231, moduleTitle=Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd55241231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603209, encodeId=fe2016032097c, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=ASCO 2014：Ibrutinib对治疗复发或难治慢性淋巴细胞白血病疗效显著, objectType=article, longId=36099, objectId=5e5d360990f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e5d360990f, replyNumber=0, likeNumber=77, createdTime=2014-06-08, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e5d360990f, moduleTitle=ASCO 2014：Ibrutinib对治疗复发或难治慢性淋巴细胞白血病疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e5d360990f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603208, encodeId=d4541603208fc, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率, objectType=article, longId=28447, objectId=80c32844e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80c32844e10, replyNumber=0, likeNumber=86, createdTime=2013-12-25, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80c32844e10, moduleTitle=Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80c32844e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603207, encodeId=8f1c160320eb7, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤, objectType=article, longId=27987, objectId=44192e98757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44192e98757, replyNumber=0, likeNumber=93, createdTime=2013-12-15, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44192e98757, moduleTitle=FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44192e98757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603206, encodeId=d0501603206b7, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请, objectType=article, longId=26204, objectId=73002620458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73002620458, replyNumber=0, likeNumber=92, createdTime=2013-11-06, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73002620458, moduleTitle=杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73002620458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603205, encodeId=c59f160320556, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=强生向欧盟提交血癌药物Ibrutinib上市许可申请, objectType=article, longId=26141, objectId=92da26141bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92da26141bf, replyNumber=0, likeNumber=112, createdTime=2013-11-03, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92da26141bf, moduleTitle=强生向欧盟提交血癌药物Ibrutinib上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92da26141bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1603204, encodeId=5071160320484, content=<a href='/topic/show?id=5512931805' target=_blank style='color:#2F92EE;'>#ibrutinib#</a>, objectTitle=ibrutinib与rituximab联合用药治疗慢性淋巴细胞白血病, objectType=article, longId=13066, objectId=20f013066c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20f013066c6, replyNumber=0, likeNumber=0, createdTime=2012-12-16, rootId=0, userName=xsm924, userId=3a6318999355, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20f013066c6, moduleTitle=ibrutinib与rituximab联合用药治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20f013066c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ibrutinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#甲氨蝶呤# #ibrutinib# #中枢神经系统淋巴瘤#

老年原发中枢神经系统淋巴瘤患者一线大剂量甲氨蝶呤化疗后Ibrutinib维持的2期研究

2024-01-06发表于陕西省

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-01-17

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2021-10-07

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

JACC：Ibrutinib药物会出现严重的心脏毒性反应

2019-09-27

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

NEJM：venetoclax联合ibrutinib一线治疗慢性淋巴细胞白血病

2019-06-02

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤

2018-06-15

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Blood：Ibrutinib治疗慢性移植物抗宿主病的疗效。

2017-09-21

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

JCO：Ibrutinib治疗慢性淋巴细胞白血病后失败怎么办？抗CD19抗体提供新思路

2017-07-21

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

JCI:通过Ibrutinib治疗可改善白血病患者的T细胞数量和功能

2017-07-21

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？

2016-12-29

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

ASH 2016：Ibrutinib治疗慢性CVHD，疗效如何？

2016-12-22

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Lancet Oncol：Ibrutinib治疗超高危CLL，风险获益良好

2016-10-08

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥

2015-12-08

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Clin Cancer Res：Ibrutinib治疗能抑制BTK和VLA-4依赖粘附的慢性淋巴细胞白血病

2015-06-25

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

ASCO 2014：Ibrutinib对治疗复发或难治慢性淋巴细胞白血病疗效显著

2014-06-08

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率

2013-12-25

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤

2013-12-15

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请

2013-11-06

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

强生向欧盟提交血癌药物Ibrutinib上市许可申请

2013-11-03

xsm924 (审核中...)

前往app查看评论内容

#ibrutinib#

ibrutinib与rituximab联合用药治疗慢性淋巴细胞白血病

2012-12-16

科室
- - 订阅+
  - 更多科室
工具
服务